HIF prolyl hydroxylase inhibitor FG-4497 enhances mouse hematopoietic stem cell mobilization via VEGFR2/KDR by Bisht, Kavita et al.
REGULAR ARTICLE
HIF prolyl hydroxylase inhibitor FG-4497 enhances mouse hematopoietic
stem cell mobilization via VEGFR2/KDR
Kavita Bisht,1,* Marion E. Brunck,1,* Taichi Matsumoto,1,2 Crystal McGirr,1 Bianca Nowlan,1 Whitney Fleming,1 Thomas Keech,1
Graham Magor,1 Andrew C. Perkins,1 Julie Davies,1 Gail Walkinshaw,3 Lee Flippin,3 Ingrid G. Winkler,1,4 and Jean-Pierre Levesque1,4
1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia; 2Faculty of
Pharmacological Sciences, Fukuoka University, Fukuoka, Japan; 3FibroGen, Inc., San Francisco, CA; and 4Faculty of Medicine, The University of Queensland, Herston,
QLD, Australia
Key Points
• VEGFR1/2 kinase in-
hibitor and neutralizing
anti-VEGFR2 antibody
block PHD inhibitor
FG-4497–mediated
increase in HSPC
mobilization.
• The inhibitory effect of
anti-VEGFR2 on HSPC
mobilization is likely
HSPC extrinsic, as
VEGFR2 is only
detected in BM
endothelial cells.
In normoxia, hypoxia-inducible transcription factors (HIFs) are rapidly degraded within
the cytoplasm as a consequence of their prolyl hydroxylation by oxygen-dependent prolyl
hydroxylase domain (PHD) enzymes. We have previously shown that hematopoietic stem
and progenitor cells (HSPCs) require HIF-1 for effective mobilization in response to
granulocyte colony-stimulating factor (G-CSF) and CXCR4 antagonist AMD3100/plerixafor.
Conversely, HIF PHD inhibitors that stabilize HIF-1 protein in vivo enhance HSPC
mobilization in response to G-CSF or AMD3100 in a cell-intrinsic manner. We now show
that extrinsic mechanisms involving vascular endothelial growth factor receptor-2
(VEGFR2), via bone marrow (BM) endothelial cells, are also at play. PTK787/vatalanib, a
tyrosine kinase inhibitor selective for VEGFR1 and VEGFR2, and neutralizing anti-VEGFR2
monoclonal antibodyDC101blocked enhancement ofHSPCmobilizationbyFG-4497.VEGFR2
was absent on mesenchymal and hematopoietic cells and was detected only in Sca11
endothelial cells in the BM. We propose that HIF PHD inhibitor FG-4497 enhances HSPC
mobilization by stabilizing HIF-1a in HSPCs as previously demonstrated, as well as by
activating VEGFR2 signaling in BM endothelial cells, which facilitates HSPC egress from
the BM into the circulation.
Introduction
Hematopoietic stem and progenitor cell (HSPC) mobilization from the bone marrow (BM) into the blood
is the mainstream procedure to harvest HSPCs for transplantation. Daily injection of granulocyte colony-
stimulating factor (G-CSF) is the standard to elicit therapeutic HSPC mobilization in humans.1 The
mechanisms of HSPC mobilization in response to G-CSF are complex. They involve indirect mechanisms
in which the BM microenvironment and HSPC niches are altered, reducing HSPC retention within their
BM niches together with some direct mechanisms promoting direct emigration of HSPCs out of their
niches toward the circulation.2-8 We have recently demonstrated that 1 of these direct mechanisms
involves the stabilization and activation of hypoxia-inducible transcription factor (HIF)-1.9 Indeed,
conditional deletion of the Hif1a gene in mouse HSPCs abrogates their mobilization in response to
G-CSF or AMD3100.9 In addition to HIF-1’s role in HSPC mobilization, conditional deletion of the
Hif1a gene in hematopoietic and stromal compartments impairs hematopoietic stem cell (HSC)
quiescence and self-renewal,10 whereas selective Hif1a deletion in hematopoietic cells does not impair
HSC function.11 Genetic stabilization10 or pharmacological stabilization12 of HIFs increases HSC
quiescence and reconstitution potential in vivo. HIF-1a protein abundance is posttranslationally
regulated, in part, by oxygen in the extracellular milieu. In the presence of an O2 concentration . 5%,
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HIF-1a protein is rapidly degraded in the cytosol before its nuclear
translocation.13 HIF-1a O2-dependent degradation is triggered by
3 HIF O2-dependent 4-prolyl hydroxylase domain (PHD) enzymes
(HIF PHD 1-3) that hydroxylate specific proline residues within HIF-1a
oxygen-dependent degradation domains.14-16 These 3 HIF PHD en-
zymes are Fe21-dependent dioxygenases using a-ketoglutarate and
oxygen as substrates. They can be inhibited in vitro and in vivo with
selective small synthetic inhibitors, such as FG-4497, a modified
isoquinoline linked to a carbonyl amino acetic acid17 that mimics and
competes with a-ketoglutarate in HIF PHD catalytic center.18,19
FG-4497 selectively inhibits HIF PHD1-3 enzymeswith a 50% inhibitory
concentration (IC50) between 0.2 and 0.3 mM,
20 thereby preventing
HIF-1a and HIF-2a prolylhydroxylation and subsequent ubiquitination
and degradation by the von Hippel-Lindau complex. Stabilized HIF-1a
and HIF-2a proteins complex to aryl hydrocarbon receptor nuclear
translocator in the cytosol for subsequent nuclear translocation where
HIFs can activate transcription of target genes.17 FG-4497 has
a .100 to 200–fold higher IC50 (40 mM) for closely related HIF
transmembrane prolyl 4-hydroxylase P4H-TM,20 but its activity against
other a-ketoglutarate dioxygenases has not been reported.
We have previously demonstrated that FG-4497 and other HIF PHD
inhibitors synergistically enhance HSPC mobilization in response to
G-CSF or AMD31009 in the C57BL/6 inbred mouse strain, which
mobilizes poorly in response to G-CSF21 and, therefore, may represent
a model of poor mobilization. The lack of an FG-4497–mobilizing effect
in mice with conditional deletion of the Hif1a gene in HSPCs
confirmed that the promobilizing effect of FG-4497 was not an off-
target effect; instead, it was mediated by HIF-1a, in part via an HSPC-
intrinsic mechanism.9 Furthermore, in nonobese diabetic severe
combined immune-deficient Il2rg2/2 mice that were irradiated and
transplanted with human cord blood CD341HSPCs, administration of
FG-4497 partially rescued the mobilization defect in human HSPCs in
response to G-CSF that is observed in these humanized mice.22
Although not completely understood, the promobilizing effect of HIF
PHD inhibitors, such as FG-4497, may be mediated by reducing the
CXCR4 intracellular pool in HSPCs and decreasing their chemotactic
response to CXCL12.9 In addition to these HSPC-intrinsic mecha-
nisms, there is evidence that HIF PHD inhibitors enhance HSPC
mobilization via niche-mediated extrinsic mechanisms, because PHD
inhibitors also reduce Cxcl12 messenger RNA (mRNA) expression
by BM stromal cells in response to G-CSF.9
Considering that HIF-1 and HIF-2 are well known to activate the
transcription of vascular endothelial growth factor-A (VEGF-A),23,24
Vegfa mRNA expression is increased in the endosteal region of the
BM of mice treated with G-CSF,25 and chronic VEGF-A administration
elicits HSPC mobilization in mice,26 we tested the hypothesis that
the promobilizing effect of HIF PHD inhibitor FG-4497 on HSPCs in
response to G-CSF involves VEGF-A and VEGF receptors (VEGFRs).
Materials and methods
Mice
All experiments were performed on 8- to 9-week-old C57BL/6 male
mice purchased from the Animal Resource Centre (Perth, Australia) and
approved by the University of Queensland Animal Ethics Committee.
In vivo treatments
VEGFR1 and VEGFR2 tyrosine kinase activity was blocked in
vivo by gavaging mice with synthetic tyrosine kinase inhibitor
PTK787/vatalanib27 (Biorbyt, Cambridge, United Kingdom; 20mg/mL
in polyethylene glycol 2000 [Fluka] at 37°C). Mice were gavaged daily
with 100 mL/20 g body weight of this suspension, corresponding to
100 mg/kg vatalanib. Control mice were gavaged with an equivalent
volume of vehicle.
HIF-1a protein was stabilized in vivo by injecting FG-4497 daily
(20 mg/kg, intraperitoneally).9,12 Control animals were injected
with an equivalent volume of 5% dextrose (weight to volume ratio)
in water.
VEGFR2 was specifically inhibited in vivo using the neutralizing
rat anti-mouse VEGFR2 monoclonal antibody (mAb) DC101.26
Purified endotoxin-free DC101 mAb (Bio-X-Cell, Lebanon, NH) was
injected intraperitoneally (800 mg, every other day).26 Control mice
were injected with 800 mg of isotype-matched rat IgG1 mAb clone
HRPN (Bio-X-Cell).
Recombinant human G-CSF (filgrastim; Amgen, Thousand Oaks,
CA) was injected twice daily (125 mg/kg, subcutaneously). Control
mice were injected with saline.
Additional materials and methods used in this study are described
in supplemental Methods.
Results
VEGFR kinase inhibitor PTK787 abrogates the
promobilizing effect of FG-4497
To test the possible involvement of VEGF-A and VEGFRs in the
promobilizing effect of the PHD inhibitor FG-4497 on HSPC
mobilization in response to G-CSF, C57BL/6 mice were mobilized
with FG-4497 or vehicle for 3 days, together with G-CSF for the last
2 days (Figure 1A); we have previously shown that this schedule
further enhances HSPC mobilization in response to G-CSF.9
Half of the mice were also gavaged for 3 consecutive days with
vehicle or PTK787 (vatalanib), which selectively inhibits VEGFR1
and VEGFR2 tyrosine kinase activities (IC50 5 77 and 37 pM,
respectively) and, to a lesser degree, VEGFR3, PDGFR-b, and
c-Kit tyrosine kinase activities (IC50 5 660, 730, and 580 pM,
respectively27).
PTK787 administration, together with G-CSF and FG-4497, abrogated
the enhancing effect of FG-4497 on G-CSF–induced mobilization
of colony-forming cells (CFCs), Lin2Kit1Sca11 (LKS1) immature
HSPCs, and phenotypic LKS1CD482CD1501 HSCs, despite the
fact that PTK787 did not alter HSPC mobilization in response to
G-CSF alone (Figure 1B-G; supplemental Figure 1). This suggests
that tyrosine kinases inhibited by PTK787 are involved in increased
HSPC mobilization in response to FG-4497.
VEGF-A increases in G-CSF–mobilized BM, and
VEGFR1 and VEGFR2 are expressed by endothelial
cells in the BM
PTK787 is a potent inhibitor of VEGFR1 and VEGFR2 tyrosine
kinases, and both of these kinases are activated by the binding of
their common ligand VEGF-A.28,29 We found that VEGF-A protein
concentration was increased in mouse BM fluids culminating at
day 4 of G-CSF administration (Figure 2A). To determine whether
VEGF-A receptors are expressed on HSPCs, we sorted LKS1 cells
from the BM of mice treated for 2 days with saline or G-CSF,
extracted RNA, and performed RNA-sequencing (RNA-seq).
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Although mRNA for Kit, Ly6a (encoding Sca1 antigen), and Flt3
was abundantly expressed as expected, mRNA for Flt1 (VEGFR1),
Kdr (VEGFR2), Flt4 (VEGFR3), and Vegfa was not detected in
LKS1 cells in steady-state or mobilized BM (Figure 2B). Our
RNA-seq results are in agreement with expression microarray
data from 39 sorted mouse HSPC subsets in the Gene Expression
Commons database30 (supplemental Figure 2). Flt1, Kdr, and Flt4
mRNA was exclusively expressed by CD452Ter1192CD512
Tie21 endothelial cells, whereas Vegfa was absent from all cell
types in this database (data not shown). To further refine this
analysis at the single-cell level, we used the Single-Cell Gene
Expression Atlas (http://blood.stemcells.cam.ac.uk/single_cell_
atlas.html), which quantifies mRNA in single cells in the full spec-
trum of HSPCs, from HSCs to myeloid progenitor cells.31 The
distributions of Lin2Kit+Sca12 (LKS2) hematopoietic progenitor
cells (HPCs), LKS1 HSPCs, LKS1CD342Flt32 HSCs, and
Slamf1 (CD150) and Procr (endothelial protein C receptor
CD201) mRNA, which is expressed by HSCs,32,33 are shown to
illustrate the different HSPC subsets. Flt1 and Flt4 mRNA was
detected in very rare single cells, whereas Kdr mRNA was
detected in few cells within the HSC region (Figure 2C). Vegfa
mRNA was detected in few cells scattered through the entire
HPC spectrum.
We next performed flow cytometry with direct fluorescent conjugates
of rat anti-mouse VEGFR1 and anti-mouse VEGFR2 mAbs to detect
them at the surface of adult mouse BMHSPCs. In pilot experiments,
we tested these antibodies on the immortalized mouse yolk sac
endothelial cell line C16634 and the mouse mesenchymal progenitor
cell line Kusa4b10.35 As expected, anti-VEGFR1 and anti-VEGFR2
antibodies bound to C166 endothelial cells but not to Kusa4b10
mesenchymal cells (supplemental Figure 3). When used on BM
leukocytes, neither VEGFR1 nor VEGFR2 proteins were detected
at the surface of any HSPC subset, including HSCs, by flow
cytometry (supplemental Figure 4).
Because some macrophage subsets reportedly express endothelial
receptor tyrosine kinase receptors, such as Tie2,36 and granulocytes2,3
and BM-resident macrophages37,38 regulate the levels of CXCL12 and
VCAM-1 protein and mRNA expression in BM hematopoietic niches in
the BM, whereas subsets of blood granulocytes express VEGFR1 but
not VEGFR2,39 we also assessed VEGFR1 and VEGFR2 proteins on
BMgranulocytes andmacrophage subsets that we could identify using
a combination of anti-F4/80, anti-Ly6G, CD169, anti–VCAM-1, and
CD11b antibodies (supplemental Figure 4). With the exception of
the CD11b1F4/801Ly6G1VCAM11CD1691 population, which had
0.2% cells positive for VEGFR1 and VEGFR2, VEGFR1 and VEGFR2
were not detected on the other BM myeloid subsets (supplemental
Figure 5), consistent with data from the Gene Expression Commons
database (supplemental Figure 2).
To measure VEGFR1 and VEGFR2 expression on BM stromal
cells, we first enriched BM endosteal cells in nonhematopoietic
stromal cells by magnetic depletion of CD451 leukocytes and
Ter1191 erythroid cells and then stained CD452Ter1192CD311
endothelial cells and CD452Ter1192CD312 mesenchymal cells
with VEGFR1 and VEGFR2 mAbs. VEGFR2 was primarily expressed
on Sca11 endothelial cells (CD452Ter1192CD311Sca11) (Figure 3).
VEGFR2 was not expressed on mesenchymal cells, such as
CD452Ter1192CD312PDGFRa1Sca11 cells, CD452Ter1192
CD312PDGFRa1Sca12 cells (also defined as CXCL12-abundant
reticular cells40), or CD452Ter1192CD312PDGFRa2Sca12 cells
(Figure 3). VEGFR1 was detected on the subset of Sca11 endothelial
cells also expressing VEGFR2, as well as on a small percentage of
CD452Ter1192CD312PDGFRa1Sca12 cells. Our flow cytometry
results for VEGFR2 are consistent with the expression of Kdr mRNA
exclusively in CD452Tie21 endothelial cells in the Gene Expression
Commons database (supplemental Figure 2); further validation by
real-time quantitative reversed transcription polymerase chain
reaction (qRT-PCR) would be needed to confirm the flow
cytometry detection of VEGFR1 on mesenchymal cells.
To confirm our flow cytometry results, CD11b1 macrophages,
CD11b2 macrophages, monocytes, granulocytes, endothelial cells,
and mesenchymal progenitor cells were sorted from the BM of mice
treated with saline or FG-4497 alone for 3 days (n5 5 per group). The
next day, a similar sorting was performed using cells from mice treated
with G-CSF alone or in combination with FG-4497. Kdr mRNA was
exclusively detected in CD452Ter1192CD311 endothelial cells and
was absent from all myeloid and mesenchymal populations
tested (Figure 3D). Furthermore, we observed that treatment with
FG-4497 alone caused a trend toward higher Kdr expression in BM
endothelial cells compared with vehicle-treated animals.
Therefore, in the adult mouse BM, VEGFR2 could only be detected
in Sca11 endothelial cells, and it was expressed at a much higher
frequency than VEGFR1 on this subset.
In vivo neutralization of VEGFR2 inhibits the
promobilizing effect of FG-4497 in response
to G-CSF
Because VEGFR2 is themost abundantly expressed VEGFR in theBM,
we neutralized VEGFR2 in vivo by administering the rat anti-mouse
VEGFR2 mAb DC101 to mice mobilized with G-CSF alone or G-CSF
plus FG-4497 (Figure 4A). Control mice were administered the isotype-
matched rat IgG1 HRPN. Mice treated with the combination of G-CSF
plus FG-4497 and control rat IgG1 mobilized CFCs, LKS1HPCs, and
phenotypic HSCs into blood and spleens significantly more than in
other treatment groups. In particular, treatment with the combination
of G-CSF plus FG-4497 and anti-VEGFR2 mAb DC101 returned
mobilization of these cells to levels equivalent to the G-CSF–alone
group (Figures 4B-G; supplemental Figure 6). Therefore, in vivo
neutralization of VEGFR2 with blocking mAb DC101 inhibited most
of the HSPC mobilization enhancement caused by FG-4497.
To further assess the effect of DC101 in vivo, we measured the
concentration of VEGF-A, the main ligand of VEGFR2,29 in the
Figure 1. VEGFR tyrosine kinase inhibitor PTK787 inhibits synergistic effect of FG-4497 on G-CSF–induced HSPC mobilization. (A) Mice were administered
G-CSF for 2 days, FG-4497 or vehicle for 3 days, and PTK787 or vehicle for 3 days. At harvest, the numbers of CFCs (B-C), LKS1 HSPCs (D-E), and LKS1CD482CD1501
HSCs (F-G) were measured in peripheral blood (B,D,F) and spleen (C,E,G). Data are from 2 pooled experiments performed several months apart. Each point represents an
individual mouse. Bars are means 6 standard deviation. *P , .05, **P , 1022, ***P , 1023, ****P , 1024. G, G-CSF with vehicles; G1F, G-CSF plus FG-4497; G1F1P,
G-CSF plus FG-4497 plus PTK787; G1P, G-CSF plus PTK787.
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blood plasma and BM fluids of these mice (Figure 5). Two-day
G-CSF treatment increased VEGF-A concentration in the
blood slightly (albeit nonsignificantly by 1-way analysis of variance
[ANOVA]), irrespective of whether FG-4497 was present (Figure 5A).
Remarkably, DC101 administration caused a fourfold increase
in blood VEGF-A concentration. A similar pattern was observed
in BM fluids (Figure 5B). Therefore, VEGF-A binding to VEGFR2
may contribute to a large proportion of VEGF-A internalization
and elimination by endothelial cells, consistent with increased
VEGFR2 expression in endothelial cells in response to FG-4497
(Figure 3D) or, alternatively, a compensation feedback due
to VEGFR2 signaling blockade may take place, leading to
enhanced VEGF-A production.
VEGF-A is produced by BM myeloid and stromal cells
but has no direct chemotactic effect on HSPCs
Because VEGF-A is increased in the BM fluids of G-CSF–mobilized
mice, particularly following DC101 mAb treatment, we sought to
determine which cell type could be the source of enhanced VEGF-A
protein in the BM. In silico analysis of the Gene Commons Database
showed that Vegfa mRNA was not detected in sorted hematopoietic
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and stromal cells from the BM in the steady-state (data not shown),
possibly due to low sensitivity of the probes used. Because
we and other investigators have previously demonstrated that
BM-resident macrophages regulate HSC niche function and
mobilization,37,38,41 and in silico data from BioGPS revealed that
bacterial lipopolysaccharides strongly stimulate Vegfa transcription
in BM macrophages (supplemental Figure 7), mouse BM-derived
macrophages (BMDMs) were cultured with mouse CSF-1 for 1 week,
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12 FEBRUARY 2019 x VOLUME 3, NUMBER 3 HIF PHD INHIBITOR INCREASES MOBILIZATION VIA KDR 411
.For personal use onlyon February 28, 2019. by guest  www.bloodadvances.orgFrom 
-1 0 +1 +2
Harvest
Days
FG-4497 or vehicle
DC101 or rat IgG1
G-CSF
A
B 3000 *
2000
CF
U 
/ m
L 
blo
od
1000
0
G+lgG G+DC G+F+
IgG
G+F+DC V
80000
60000
CF
U 
/ s
ple
en
40000
20000
0
***
G+lgG G+DC G+F+
IgG
G+F+DC V
C
3000
4000
2000
LK
S+
 c
ell
s /
 m
L 
blo
od
1000
0
G+lgG G+DC G+F+
IgG
G+F+DC V
**
D
1000000
800000
600000
400000
200000
0
LK
S+
 c
ell
s /
 sp
lee
n
G+lgG G+DC G+F+
IgG
G+F+DC V
***E
LK
S+
 C
D4
8-
 C
D1
50
+ 
ce
lls
 / 
m
L 
blo
od
250
200
150
100
50
0
G+lgG G+DC G+F+
IgG
G+F+DC V
p=0.107F
LK
S+
 C
D4
8-
 C
D1
50
+ 
ce
lls
 / 
sp
lee
n
40000
30000
20000
10000
0
G+lgG G+DC G+F+
IgG
G+F+DC V
***G
Figure 4. Neutralization of VEGFR2 blocks the effect of FG-4497 on G-CSF–induced HSPC mobilization. (A) Mice were administered G-CSF for 2 days, FG-4497
or vehicle for 3 days, and neutralizing rat anti-mouse VEGFR2 mAb DC101 or control rat IgG1 every other day. At harvest, the numbers of CFCs (B-C), LKS1 HSPCs (D-E),
and LKS1CD482CD1501 HSCs (F-G) were measured in peripheral blood (B,D,F) and spleen (C,E,G). Data are from 2 pooled experiments performed several months apart.
Each point is an individual mouse. Bars are means 6 standard deviation. *P , .05, **P , 1022, ***P , 1023. G1DC, G-CSF with vehicle DC101 mAb; G1F1DC, G-CSF
plus FG-4497 plus DC101; G1F1IgG, G-CSF plus FG-4497 plus rat IgG1; G1IgG, G-CSF with vehicle with rat IgG1.
412 BISHT et al 12 FEBRUARY 2019 x VOLUME 3, NUMBER 3
.For personal use onlyon February 28, 2019. by guest  www.bloodadvances.orgFrom 
500
***
*
*
*
*
400
300
VE
GF
-A
, p
g/
m
L 
blo
od
200
100
0
G+lgG G+F+
lgG
G+F+DC VG+DC
A
300
* * * ****
*
***
VE
GF
-A
, p
g 
/ f
em
ur
200
100
0
G+lgG G+F+
lgG
G+F+DC VG+DC
B
****
****
****
****
****
****
****
****
40
VE
GF
-A
, p
g/
m
L
20
0
C G+F C G F G+FFG
24hrs 48hrs
C kDa
HIF-1
-actin
150
100
50
37
G-CSF - + - + - + - +
- - +
24h 48h
+ - - + +FG-4497
D
0.0
CD11b+M CD11b-M MO Gran
0.5
C
F
G
G+F
1.0
Ve
gf
c 
m
RN
A 
re
lat
ive
 to
 H
pr
t
2.0
1.5
2.5
0
EC P±S+ P+S- P-S-
2
4
Ve
gf
c 
m
RN
A 
re
lat
ive
 to
 H
pr
t
8
6
10
C
F
G
G+F
****
***
****
*
*
CD11b+M CD11b-M MO Gran
C
F
G
G+F
Ve
gf
d 
m
RN
A 
re
lat
ive
 to
 H
pr
0.0
0.5
1.0
2.0
1.5
2.5
0
EC P±S+ P+S- P-S-
1
Ve
gf
d 
m
RN
A 
re
lat
ive
 to
 H
pr
t
3
2
4
C
F
G
G+F
*
*
0.054
E
0.0
CD11b+M CD11b-M MO Gran
0.5
C
F
G
G+F
1.0
Ve
gf
a 
m
RN
A 
re
lat
ive
 to
 H
pr
t
2.0
1.5
2.5 *
**
*
*
*
*
C
F
G
G+F
*
* *
**
*
**
**
**
EC P±S+ P+S- P-S-
Ve
gf
a 
m
RN
A 
re
lat
ive
 to
 H
pr
t
0
10
20
30
90
30
60
120
*
Figure 5.
12 FEBRUARY 2019 x VOLUME 3, NUMBER 3 HIF PHD INHIBITOR INCREASES MOBILIZATION VIA KDR 413
.For personal use onlyon February 28, 2019. by guest  www.bloodadvances.orgFrom 
followed by 48 hours in the presence or absence of 100 ng/mL
recombinant human G-CSF (rhuG-CSF) or 40 mM FG-4497. By
enzyme-linked immunosorbent assay, FG-4497 strongly stimulated
VEGF-A secretion by BMDMs in vitro, whereas G-CSF did not
(Figure 5C). Western blotting of the BMDM pellets showed that
HIF-1a protein was stabilized in conditions containing 40 mM
FG-4497, whereas G-CSF was unable to stabilize HIF-1a protein.
Therefore, stabilization of HIF-1a by FG-4497 is a strong stimulator
of VEGF-A transcription and secretion by BMDMs in vitro, as
previously shown in different malignant cell lines.23,24
To validate these results in vivo, we repeated qRT-PCR on CD11b1
macrophages, CD11b2 macrophages, monocytes, granulocytes,
endothelial cells, and mesenchymal progenitor cells sorted from
the BM, as in Figure 3D, using Vegfa and Hprt primer–probe sets
(Figure 5D). In vivo FG-4497 treatment significantly increased
VegfamRNA in CD11b1macrophages (Figure 5E), similar to BMDMs
(Figure 5D), but not in other BM myeloid cells. Compared
with saline, FG-4497 treatment also significantly increased
Vegfa mRNA in Sca11 mesenchymal progenitor cells (P 5 .002,
Student t test), which include CXCL12-abundant reticular cells,
and also caused a trend increase in more mature PDGFRa1Sca12
mesenchymal progenitor cells (P 5 .059). ANOVA confirmed
pronounced Vegfa induction in response to G-CSF in CD11b1
macrophages, monocytes, and Sca11 and PDGFRa1Sca12 mesen-
chymal progenitor cells. qRT-PCR for the 2 alternative VEGFR2
ligands Vegfc and Vegfd showed that, although these 2
cytokines were not expressed by BM myeloid cells in any
condition, FG-4497 treatment increased Vegfc and Vegfd mRNA
expression in Sca11 mesenchymal progenitor cells and Vegfc
expression in PDGFRa1Sca12 mesenchymal progenitor cells
(Figure 5E).
We next assessed whether recombinant mouse VEGF-A164 had
chemotactic effect or modulated chemotaxis of HSPCs. First, we
verified that purified recombinant mouse VEGF-A was bioactive by
measuring phosphorylation of VEGFR2 and Akt kinases in C166
endothelial cells (supplemental Figure 8). VEGF-A (100 ng/mL)
added to the bottom chamber of a chemotaxis assay did not induce
chemotaxis of HSPCs, whereas CXCL12 (50 ng/mL) did (Figure 6).
To assess whether VEGF-A could modulate chemotaxis in response
to the CXCL12 gradient, CXCL12 was added to the bottom
chamber and VEGF-A was added to the top or bottom chamber
with DC101 or control HRPN mAb. Neither VEGF-A nor DC101
mAb altered migration of mouse HPSCs in response to the CXCL12
gradient. Therefore, VEGF-A or VEGFR2 neutralization has no
direct effect on HSPC chemotactic response to the CXCL12
gradient, further suggesting that the inhibitory effect of PTK787
and DC101 mAb on HSPC mobilization induced by G-CSF and
FG-4497 is mediated indirectly. Considering that Sca11 endothe-
lial cells are the only ones that express VEGFR2 in BM tissue, these
are the most likely candidates to fill this role.
In vivo neutralization of VEGFR2 does not alter
CXCL12 concentration in the BM
We next measured whether in vivo treatment with DC101 mAb
altered CXCL12 concentration in the BM. G-CSF treatment
for 2 days reduced CXCL12 concentration in BM fluids 2.5-fold
(supplemental Figure 9), as previously reported.2 Treatment with
G-CSF 1 FG-4497 caused a slight, but significant, additional
decrease in CXCL12 concentration, in agreement with a previously
reported decrease in Cxcl12 mRNA concentration.9 Surprisingly,
however, in vivo neutralization of VEGFR2 with DC101 mAb
did not alter CXCL12 concentration compared with mice treated
with isotype control.
Discussion
With .1 million transplantations performed using mobilized blood
HSPCs worldwide, this procedure has proven its benefits in improving
the clinical outcome of hematological malignancies, such as acute
myeloid leukemias,42,43 lymphoma,44 and myeloma.45 However,
in the context of autologous transplantation, prior chemotherapy
treatments and diseased BM can impair the mobilizing response
to G-CSF in a high proportion of patients.1 Therefore, uncovering
the cellular and molecular mechanisms of HSPC mobilization is
essential to find novel treatment options to increase HSPC mobiliza-
tion in these poor mobilizers, as exemplified by the recent approval
of use of the CXCR4 antagonist plerixafor in combination with
G-CSF for this purpose.1,2,46-49
HIF PHD inhibitors, such as FG-4497, synergize with G-CSF to
enhance mouse HSPCmobilization in the C57BL/6 mouse strain,17
as well as that of human HSPCs transplanted in irradiated immune-
deficient mice,26 2 models of poor mobilization.21,50 This effect is,
in part, HSPC intrinsic and HIF-1 mediated, because conditional
deletion of theHif1a gene specifically in HSPCs impairs the mobilizing
effect of FG-4497 on HSPCs in response to G-CSF.9 However,
this does not exclude an HSPC-extrinsic effect mediated by niche
cells. Herein, we show that the effect of FG-4497 on G-CSF–induced
HSPC mobilization also involves stimulation of VEGFR2 signaling,
because the FG-4497 effect is inhibited by PTK787, a small
tyrosine kinase inhibitor selective for VEGFR1 and VEGFR2,27
as well as by DC101, a neutralizing anti-VEGFR2 mAb.
Figure 5. VEGF-A concentration is increased in vivo in response to DC101 and in vitro in response to FG-4497. (A-B) Mice were treated with G-CSF, FG-4497,
neutralizing rat anti-mouse VEGFR2 mAb DC101, or control rat IgG1, as described in Figure 4A. Mouse VEGF-A protein concentration was measured by enzyme-linked
immunosorbent assay in blood plasma (A) and femoral BM fluids (B). Data are from 2 pooled experiments performed at a 1-month interval. Each point represents an individual
mouse. (C) FG-4497 stimulated VEGF-A secretion by BMDMs in vitro. BMDMs were cultured for 48 hours in the presence of 100 ng/mL rhuG-CSF (G), 40 mM FG-4497
(F), or both (G1F). Control cells were added vehicle. Supernatants were harvested at 24 and 48 hours, and mouse VEGF-A concentration was measured by enzyme-linked
immunosorbent assay. Data are means 6 SD of 3 replicates per conditions. (D) Western blot for HIF-1a on BMDMs cultured for 24 or 48 hours in the presence of 100 ng/mL
rhuG-CSF or 40 mM FG-4497. (E) Vegfa, Vegfc, and Vegfd mRNA expression by qRT-PCR on CD11b1F4/801VCAM11CD1691 macrophages (CD11b1Mw),
CD11b2F4/801VCAM11CD1691 macrophages (CD11b-Mw), CD11b1F4/801VCAM12CD1692 monocytes (MO), CD11b1F4/802Ly6G1 granulocytes (Gran),
CD452Ter1192CD311 endothelial cells (EC), CD452Ter1192CD312PDGFRa1/2Sca11 mesenchymal progenitor cells (P6S1), PDGFRa1Sca12 mesenchymal progenitor
cells (P1S-), and CD452Ter1192CD312PDGFRa2Sca12 stromal cells (P-S-) sorted from the BM of mice treated with saline (C), FG-4497 alone (F), G-CSF (G), or G-CSF
plus FG-4497 (G1F) for 3 days. Each circle represents a separate mouse and separate sort (n 5 5 mice per population per treatment condition). Data are relative to Hprt
mRNA. *P , .05, **P , 1022, ***P , 1023, ****P , 1024, ANOVA.
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Mechanistically, we find that FG-4497 stabilizes HIF-1a protein
and increases VEGF-A protein secretion by BM macrophages in
vitro, consistent with the key role of BM macrophages in regulat-
ing HSC niches and promoting HSC mobilization in response to
G-CSF.37,38,41,51 In vivo, FG-4497 treatment alone induced Vegfa
mRNA expression in CD11b1 macrophages and Sca11 mesen-
chymal progenitor cells, whereas G-CSF alone caused a stronger
induction in CD11b2 macrophages, monocytes, and Sca11 and
PDGFRa1 mesenchymal progenitor cells. We could not detect a
significant increase in VEGF-A protein in BM fluids in response to
FG-4497 in vivo. However, additional VEGF-A produced in the BM
may have been consumed by increased VEGFR2 internalization
following FG-4497 treatment, because VEGFR2 mRNA expression
by endothelial cells was increased in response to FG-4497.
Vegfa mRNA was increased in response to G-CSF in CD11b2
macrophages, monocytes, and mesenchymal progenitor cells in
vivo, consistent with the presence of a STAT3 consensus binding
site in human and mouse Vegfa gene promoter regions24 and the fact
that G-CSF activates STAT3 phosphorylation and nuclear trans-
location in cells expressing its receptor.52,53 Interestingly, G-CSF
was unable to stimulate VEGF-A protein production by BMDMs in
vitro and CD11b1macrophages and granulocytes in vivo. Surprisingly,
we did not find a higher induction of Vegfa mRNA following G-CSF
plus FG-4497 vs G-CSF alone. Interestingly, FG-4497 treatment also
increased expression, at the RNA level, of VEGF-C and VEGF-D,
which are also VEGFR2 ligands, albeit with a weaker affinity.29
Our observation that FG-4497, which stabilizes HIF-1a protein in
the BM,9,12 increases HSPC mobilization in response to G-CSF in
a VEGFR2-dependent manner is also consistent with previous
reports showing that systemic elevation of circulating VEGF-A
causes mobilization of CFCs and radioprotective HSCs, an effect
that is blocked by neutralizing anti-VEGFR2 mAb DC101.26
Interestingly, we find that in vivo neutralization of VEGFR2 by DC101
mAb caused a dramatic increase in VEGF-A concentration in blood
and BM fluids, suggesting that most VEGF-A consumption is
caused by VEGFR2-mediated internalization by endothelial cells in
vivo or that a compensation feedback due to VEGFR2 signaling
blockade takes place, leading to enhanced VEGF-A production.
Therefore, it remains possible that our measurement of VEGF-A
protein concentration in BM fluids underestimates the increase
in VEGF-A bioavailability and signaling in the BM in response to
G-CSF and FG-4497, because of its high VEGFR2-mediated
turnover, and that VEGF-C and VEGF-D also contribute to enhanced
HSPC mobilization in response to FG-4497.
Although cell surface expression of VEGFR2 has been reported
in mouse hematopoietic precursor cells derived from embryoid
bodies,54 the expression of VEGFR1 and VEGFR2 on adult mouse
BM HSPCs remains controversial. VEGFR1 was reported on adult
BM LKS1 cells, with VEGFR11 BM mononuclear cells providing
radioprotection.55 VEGFR2 was also reported to be expressed
by radioprotective BM Lin2Kit1 cells.56 However, in a subsequent
study, VEGFR2 could not be detected at the surface of adult
LKS1CD342 Hoechst33342 side population cells, and sorted
VEGFR21 cells could not reconstitute hematopoiesis in trans-
plantation assays.57 To further assess VEGFR1 and VEGFR2
expression status in adult mouse BM HSPCs, we examined their
expression at the mRNA level by performing RNA-seq on sorted
LKS1 cells, as well as in silico analyses using a publicly available
single-cell RNA-seq database31 and the Gene Expression Com-
mons database.30 We also performed multicolor flow cytometry
with directly conjugated mAbs specific for VEGFR1 and VEGFR2
that we validated on the mouse embryonic endothelial cell line C166
(positive for both) and the mouse mesenchymal progenitor cell line
Kusa4b10 (negative for both). VEGFR1 and VEGFR2 mRNA could
not be detected in any population of Lin2Kit1Sca11 HSPCs in the
BM in steady-state or in response to G-CSF. Furthermore, in our flow
cytometry analyses, VEGFR2 was not detected at the cell surface of
BM HSPCs, myeloid cells, or mesenchymal cells but was exclusively
expressed by Sca11 endothelial cells. Likewise Kdr (VEGFR2) mRNA
could only be detected in sorted BM endothelial cells by qRT-PCR.
This suggests that VEGFR2 signaling enhances HSPCmobilization in
response to FG-4497 indirectly via BM endothelial cells expressing
VEGFR2. In support of this, VEGF-A protein or DC101 mAb had no
direct effect on LKS1 cell chemotaxis in vitro. Our findings in the adult
mouse are consistent with the lack of expression of FLT1 and KDR
mRNA on human BM CD341Kit1Rhodamine123low HSPCs and
the lack of proliferative effect of VEGF-A on these cells.58
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Figure 6. VEGF-A has no chemotactic effect on HSPCs
in vitro. Chemotaxis assay with Kit1 enriched BM cells from
naive C57BL/6 mice incubated for 4 hours at 37°C in the
presence of 50 ng/mL CXCL12 in the bottom chamber or
100 ng/mL mouse VEGF-A in the bottom chamber or in
the top insert. The percentage of LKS1 cells (A) and
LKS1CD482CD1501 HSCs (B) that migrated to the
bottom chamber was measured by flow cytometry. Data are
from 2 pooled experiments performed several weeks apart.
Each symbol is a well. Bars are means 6 standard deviation.
Each individual group with CXCL12 in the bottom well was
significantly different from each group without CXCL12.
****P , 1024, ANOVA.
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The mechanism by which VEGFR2 signaling enhances HSPC
mobilization may involve vascular remodeling in the BM.26,59 Indeed,
although FG-4497 administration, together with G-CSF, further
decreased CXCL12 in the BM compared with mice treated with
G-CSF alone, this additional decrease in CXCL12 concentration
was relatively modest compared with the decrease induced by
G-CSF treatment; therefore, it is unlikely to explain the enhanced
HSPC mobilization in response to FG-4497. On the other hand,
expression of VEGF-A by tumor cells has been shown to cause
vascular dilation, increased vascular density, and permeability to high-
molecular-weight dextran, causing leukocyte mobilization into the
circulation.59 This effect was not observed in mice bearing tumors
overexpressing placental growth factor or VEGF-B, which both
bind exclusively to VEGFR1.59 Furthermore, VEGF-A’s effect on
BM vascular dilation and BM leukocyte mobilization was blocked
by DC101 mAb or by conditional deletion of the Kdr gene in
endothelial cells, but not by a neutralizing anti-mouse VEGFR1mAb,59
demonstrating that the effect of VEGF-A on BM vascularization is
solely mediated by VEGFR2 on endothelial cells.59 Finally, the
promobilizing effect of vascular dilation has been documented
recently by showing that PDE5 inhibitor Viagra increases HSPC
mobilization in response to CXCR4 antagonist AMD3100,60 similar
to the effect of FG-4497 on plerixafor-induced HSPC mobilization.9
In conclusion, we propose that PHD inhibitors increase HSPC
mobilization in response to G-CSF and CXCR4 antagonist
AMD31009 by 2 distinct mechanisms: (1) HSPC-intrinsic mecha-
nisms by which PHD inhibitors further stabilize HIF-1 protein in
HSPCs, enabling transcription of intracellular factors perturbing
CXCR4 internalization, which decreases HSPC chemotactic
response to CXCL12 and facilitates HSPC migration out of the
BM9 in response to the attenuation of the CXCL12 gradient
that takes place following treatment with G-CSF2,61,62 or
AMD3100,63,64 and (2) an HPSC-extrinsic mechanism involving
increased expression of VEGFR2 ligands VEGF-A, VEGF-C, and
VEGF-D in the BM, leading to increased VEGFR2 signaling in
BM endothelial cells.
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